Get started
Author

Beata Maćkowiak-Matejczyk

Observed names: B Maćkowiak-Matejczyk, B. Mackowiak-Matejczyk, B. Maćkowiak-Matejczyk, Beata Mackowiak-Matejczyk, Beata Maćkowiak-Matejczk
OpenAlex ID: A5017971571
Anti-NaPi2b antibody–drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer in a randomized, open-label, phase II study
2018 · S. Banerjee, A.M. Oza, et al. · Annals of Oncology · 102
Serum levels of IL-6, IL-8 and CRP as prognostic factors in epithelial ovarian cancer
2013 · Bozena Dobrzycka, Beata Mackowiak-Matejczyk, et al. · European Cytokine Network · 82
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial
2024 · Christian Marth, Richard G. Moore, et al. · Journal of Clinical Oncology · 77
Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study
2026 · Nicoletta Colombo, Emese Zsiros, et al. · The Lancet · 59
Preoperative HE4, CA125 and ROMA in the differential diagnosis of benign and malignant adnexal masses
2016 · Katarzyna M. Terlikowska, Bozena Dobrzycka, et al. · Journal of Ovarian Research · 52
PDF
518O Overall survival results from ARIEL4: A phase III study assessing rucaparib vs chemotherapy in patients with advanced, relapsed ovarian carcinoma and a deleterious BRCA1/2 mutation
2022 · A.M. Oza, A.S. Lisyanskaya, et al. · Annals of Oncology · 39
Prognostic significance of pretreatment VEGF, survivin, and Smac/DIABLO serum levels in patients with serous ovarian carcinoma
2015 · Bozena Dobrzycka, Beata Mackowiak-Matejczyk, et al. · Tumor Biology · 36
PDF
Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial
2025 · Ana Oaknin, Bradley J. Monk, et al. · European Journal of Cancer · 32
Pretreatment serum levels of bFGF and VEGF and its clinical significance in endometrial carcinoma
2012 · Bozena Dobrzycka, Beata Mackowiak-Matejczyk, et al. · Gynecologic Oncology · 30
Rucaparib versus chemotherapy for treatment of relapsed ovarian cancer with deleterious BRCA1 or BRCA2 mutation (ARIEL4): final results of an international, open-label, randomised, phase 3 trial
2025 · Amit M Oza, Alla Lisyanskaya, et al. · The Lancet Oncology · 29
KEYNOTE-C93/GOG-3064/ENGOT-en15: A phase 3, randomized, open-label study of first-line pembrolizumab versus platinum-doublet chemotherapy in mismatch repair deficient advanced or recurrent endometrial carcinoma.
2022 · Brian M. Slomovitz, David Cibula, et al. · Journal of Clinical Oncology · 25
Utility of HE4 to identify patients with endometrioid endometrial cancer who may require lymphadenectomy
2015 · Bozena Dobrzycka, Beata Mackowiak-Matejczyk, et al. · Advances in Medical Sciences · 18
519MO Phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial of cemiplimab in recurrent or metastatic (R/M) cervical cancer: Long-term survival analysis
2022 · A. Oaknin, B.J. Monk, et al. · Annals of Oncology · 14
1Rucaparib versus chemotherapy in patients with advanced, relapsed ovarian cancer and a deleterious BRCA mutation: efficacy and safety from ARIEL4, a randomized phase III study
2021 · Rebecca Kristeleit, Alla Lisyanskaya, et al. · Gynecologic Oncology · 11
Prevalence of Chlamydia trachomatis infection in women with cervical lesions.
2007 · V Bułhak-Kozioł, B Zdrodowska-Stefanow, et al. · PubMed · 10
Subgroup analysis of rucaparib versus chemotherapy as treatment for BRCA-mutated, advanced, relapsed ovarian carcinoma: Effect of platinum sensitivity in the randomized, phase 3 study ARIEL4.
2021 · Amit M. Oza, Alla Sergeevna Lisyanskaya, et al. · Journal of Clinical Oncology · 8
Survival With Cemiplimab in Recurrent Cervical Cancer
2022 · Krishnansu S. Tewari, Bradley J. Monk, et al. · Obstetrical & Gynecological Survey · 6
A randomized, open-label, phase II study of anti-NaPi2b antibody-drug conjugate (ADC) lifastuzumab (Lifa) vedotin (DNIB0600A) compared to pegylated liposomal doxorubicin (PLD) in patients (pts) with platinum-resistant ovarian cancer (PROC).
2016 · Susana N. Banerjee, Amit M. Oza, et al. · Journal of Clinical Oncology · 5
Quality of life during the first year after breast cancer resection
2014 · Bożena Kulesza-Brończyk, Bożena Dobrzycka, et al. · Progress in Health Sciences · 4
O009/#786 Rucaparib vs chemotherapy in patients with advanced, relapsed ovarian cancer and a deleterious brca mutation: efficacy and safety from ariel4, a randomized phase 3 study
2021 · R. Kristeleit, A. Lisyanskaya, et al. · International Journal of Gynecological Cancer · 3
Quality of life and the level of knowledge and utilization of lymphedema prevention principles among mastectomized patients
2014 · Bożena Kulesza-Brończyk, Bożena Dobrzycka, et al. · Progress in Health Sciences · 3
TP016/#1442 Keynote-C93/GOG-3064/ENGOT-EN15: phase 3, randomized, open-label study of first-line pembrolizumab versus platinum-doublet chemotherapy in mismatch repair deficient advanced or recurrent endometrial carcinoma
2022 · Brian Slomovitz, David Cibula, et al. · International Journal of Gynecological Cancer · 2
PDF
Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial
2026 · Domenica Lorusso, Jérôme Martin-Babau, et al. · The Lancet · 1
Quality-adjusted time without symptoms of disease progression or toxicity of treatment in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel versus carboplatin-paclitaxel
2025 · Dana M. Chase, Jørn Herrstedt, et al. · International Journal of Gynecological Cancer · 1
First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial
2026 · Brian M Slomovitz, Jianqing Zhu, et al. · The Lancet
Works count: 32
Citation count: 649
H-index: 13
I10-index: 15
Year
Topic
Type